Two cases of COPD benefitting from therapy with roflumilast

Abstract

Two clinical cases of chronic obstructive pulmonary disease (COPD) stage II patients are reported here. One case refers to a patient with hypoxemia associated to severe air flow limitation, chronic bronchitis and frequent exacerbation events. A significant improvement of patient’s conditions was observed after pharmacological treatment with roflumilast. The second case refers to a patient who refused to adhere to prescribed therapy but adhered to roflumilast therapy, eventually achieving a good response. Both cases highlight roflumilast’s efficacy in improving health conditions of COPD patients.

Roflumilast: the fourth Mousquetaire in COPD pharmacological treatment

“…This issue of Monaldi Archives is dedicated to real life reports of the use of roflumilast in clinical practice. After a comprehensive review on the drug and its clinical data [15], six reports from different Hospitals and groups across Italy describe similar stories [16][17][18][19][20][21]. The reports deal with patients with recurrent AECOPD episodes causing multiple hospitalization (so called "revolving door patients"), patients not responding to conventional treatments, with accelerated decline of lung function, multiple comorbidities, developing disability.…”